Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1209-1213

  Perea, Sofia ^a   Pennick, Gennethel J ^a   Modak, Asha ^a   Fothergill, Annette W ^a   Sutton, Deanna A ^a   Sheehan, Daniel J ^c   Rinaldi, Michael G ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MYCOSIS; PATIENT MONITORING; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; BIOLOGICAL ASSAY; CANDIDA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EVALUATION STUDIES; HUMANS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; TRIAZOLES;

EID: 0034007446     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1209-1213.2000     Document Type: Article

References (21)

1. Bailey, E. M., D. J. Krakovsky, and M. J. Rybak. 1990. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 10:146-153.
2. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949.
3. Belanger, P., C. C. Nast, R. Fratti, H. Sanati, and M. Ghannoum. 1997. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1840-1842.
4. Caillot, D., O. Casanovas, A. Bernard, J. F. Couaillier, C. Durand, B. Cuisenier, E. Solary, F. Piard, T. Petrella, A. Bonnin, G. Couillault, M. Dumas, and H. Guy. 1997. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol. 15:139-147.
5. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
6. George, D., P. Miniter, and V. T. Andriole. 1996. Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 40:86-91.
7. Girmenia, C., G. Luzi, M. Monaco, and P. Martino. 1998. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J. Clin. Microbiol. 36:1436-1438.
8. Hostetler, J. S., J. Heykants, K. V. Clemons, R. Woestenborghs, L. H. Hanson, and D. A. Stevens. 1993. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob. Agents Chemother. 37:2224-2227.
9. Marco, F., M. A. Pfaller, S. Messer, and R. N. Jones. 1998. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 42:161-163.
10. Martin, M. V., J. Yates, and C. A. Hitchcock. 1997. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob. Agents Chemother. 41:13-16.
11. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. Cooper, and M. G. Rinaldi. 1997. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41:1832-1834.
12. Mueller, H. W., and J. Eitel. 1996. Quality control in the determination of Cortisol in plasma/serum by using, on every sample, two different three-step separation methods including ultrafiltration, restricted-access high-performance liquid chromatography and reverse-phase high-performance liquid chromatography and contrasting results to immunoassays. J. Chromatogr. B 678:137-150.
13. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
14. Nguyen, M. H., and C. Y. Yu. 1998. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob. Agents Chemother. 42:471-472.
15. Nguyen, M. H., and C. Y. Yu. 1998. Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J. Antimicrob. Chemother. 42:253-256.
16. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogen. Antimicrob. Agents Chemother. 41:841-843.
17. Ruhnke, M., A. Schmidt-Westhaussen, and M. Trautmann. 1997. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infections. Antimicrob. Agents Chemother. 41:575-577.
18. Schwartz, S., D. Milatovic, and E. Thiel. 1997. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute-leukemia. Br. J. Haematol. 97:663-665.
19. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
20. Stopher, D. A., and R. Gage. 1997. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J. Chromatogr. B 691:441-448.
21. Wildfeuer, A., H. P. Seidl, I. Paule, and A. Haberreiter. 1997. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin. Arzneimittel-Forschung. 47:1257-1263.